News

Filter

Current filters:

PfizerNeurontin

1 to 9 of 88 results

Pfizer loses Neurontin appeal at US Supreme Court

Pfizer loses Neurontin appeal at US Supreme Court

10-12-2013

The US Supreme Court has stood by a $142 million ruling against US drug maker Pfizer (NYSE: PFE) over…

LegalNeurontinPfizerPharmaceuticalUSA

Briefs: Pfizer $142 million fine upheld; Bristol-Myers shuts Amylin facility

05-04-2013

The US Court of Appeals in Boston has upheld a $142.1 million damage award to Kaiser Foundation Health…

AmylinBristol-Myers SquibbLegalManagementMarkets & MarketingNeurontinNorth AmericaPfizerPharmaceutical

Clinical study of epilepsy drug may have served primarily to promote drug and increase prescribing

28-06-2011

A review of documentation relating to a clinical trial of the epilepsy drug gabapentin (drug giant Pfizer’s…

Markets & MarketingNeurontinPfizerPharmaceuticalResearch

Pfizer to pay $142.1 million over off-label marketing of Neurontin

31-01-2011

Global drugs behemoth Pfizer (NYSE: PFE) has been ordered to pay a total of $142.1 million in damages…

LegalNeurologicalNeurontinPfizerPharmaceutical

Pfizer disputes NEJM findings of skewing data on Neurontin

12-11-2009

The world’s largest drugmaker, USA-based Pfizer, denies that it may have altered or omitted unfavorable…

gabapentinGeneralNeurologicalNeurontinNorth AmericaPfizerPharmaceuticalRegulation

1 to 9 of 88 results

Back to top